Seminars in Oncology
Volume 29, Issue 2 , Pages 119-125 , April 2002

Intrahepatic arterial infusion of chemotherapy: Pharmacologic principles

References 

  1. Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984;2:498–504
  2. Ensminger WD, Gyves JW. Regional cancer chemotherapy. Cancer Treat Rep. 1984;68:101–115
  3. Ensminger WD. Intraarterial therapy. In:  Perry MC editors. The Chemotherapy Source Book. Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 163–173
  4. Buchwald H, Giage TB, Vassilopoulos PP, et al.  Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer. 1980;45:866–869
  5. Ensminger W, Niederhuber J, Dakhil S, et al.  Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep. 1981;65:393–400
  6. Narsete T, Ansfeld F, Wirtanen G, et al.  Gastric ulceration in patients receiving intrahepatic infusion of 5-fluorouracial. Ann Surg. 1977;186:734–736
  7. Chuang V, Wallace S, Stroehlin J, et al.  Hepatic artery infusion chemotherapy: Gastroduodenal complications. Am J Roentgenol. 1981;137:347–350
  8. Stephens FO, Waugh RC, Prest G. Radiological versus surgical placement of cannulas for delivery of intra-arterial chemotherapy. Reg Cancer Treat. 1988;1:37–43
  9. Niederhuber JE, Ensminger WD. Surgical considerations of management of hepatic neoplasia. Semin Oncol. 1983;10:135–147
  10. Curley SA, Chase JL, Roh MS, et al.  Technical considerations and complicatons associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery. 1993;114:928–935
  11. Campbell KA, Burns RC, Sitzmann JV, et al.  Regional chemotherapy devices: Effect of experience and anatomy on complications. J Clin Oncol. 1993;11:822–826
  12. Kaplan WD, D'Orsi CJ, Ensminger WD, et al.  Intra-arterial radionuclide infusion: A new technique to assess chemotherapy perfusion patterns. Cancer Treat Rep. 1978;62:699–703
  13. Andrews JC, Cho KJ, Ensminger WD. Transcatheter technique for correction of unsatisfactory perfusion following surgical placement of a hepatic artery catheter. J Int Radiol. 1986;1:93–96
  14. Hohn DC, Staff RJ, Price DC, et al.  Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2'-deoxyuridine. J Clin Oncol. 1985;3:1257–1260
  15. Niederhuber JE, Ensminger WD, Gyves JW, et al.  Regional chemotherapy of colorectal cancer metastases to the liver. Cancer. 1984;53:1336–1343
  16. Ensminger W, Rosowsky A, Raso V, et al.  A clinical-pharmacological evaluation of hepatic arterial infusion of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res. 1978;38:3784–3792
  17. Kemeny MM, Batifora H, Blayney DW, et al.  Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg. 1985;202:176–181
  18. Hohn D, Melnick J, Stagg R, et al.  Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol. 1985;3:98–102
  19. Kemeny N, Gonen M, Sullivan D, et al.  Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol. 2001;19:2687–2695
  20. Ensminger WD, Knol JA, Dou C, et al.  Biliary toxicity due to direct epithelial injury following hepatic arterial infusion of 5-fluorodeoxyuridine in a canine model. Proc Am Assoc Cancer Res. 2000;41:493; (abstr)
  21. Kemeny N, Huang Y, Cohen AM, et al.  Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–2048
  22. Lawrence TS, Dworzonin LM, Walker-Andrews SC, et al.  Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiol Oncol Biol Phys. 1991;20:555–561
  23. Dawson LA, McGinn CJ, Normolle D, et al.  Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18:2210–2218
  24. Wagner JG, Gyves JW, Stetson PL, et al.  Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res. 1986;46:1499–1506
  25. Knol JA, Stetson PL, Wagner JG, et al.  5-Bromo-2'deoxyuridine incorporation into DNA in hepatic VX2 tumor-bearing rabbits. J Surg Res. 1989;47:112–116
  26. Ensminger WD, Walker SC, Stetson PL, et al.  Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine. Cancer Res. 1994;54:2121–2124
  27. Sigurdson ER, Ridge JA, Kemeny N, et al.  Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol. 1987;5:1836–1840
  28. Kaplan WD, Come SE, Takvorian RW, et al.  Pulmonary uptake of technetium 99m macroaggregated albumin: A predictor of gastrointestinal toxicity during hepatic artery perfusion. J Clin Oncol. 1984;2:1266–1269
  29. Kemeny N, Seiter K, Conti JA, et al.  Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal cancer. Cancer. 1994;73:1134–1142
  30. Kemeny N, Conti JA, Cohen A, et al.  Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasome for unresectable liver metastases from colorectal cancer. J Clin Oncol. 1994;12:2288–2295
  31. Kemeny N, Conti JA, Sigindson E, et al.  A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. Cancer. 1993;71:1964–1971
  32. Ensminger WD. Regional chemotherapy. Semin Oncol. 1993;20:3–11

☆ W.D.E. has been a consultant to the Arrow Therex Corp, Walpole, MA.

☆☆ Address reprint requests to William D. Ensminger, MD, PhD, Departments of Internal Medicine and Pharmacology, University of Michigan Health System, Ann Arbor, MI 48109-0504.

PII: S0093-7754(02)50132-9

doi: 10.1053/sonc.2002.31679

Seminars in Oncology
Volume 29, Issue 2 , Pages 119-125 , April 2002

Article Tools

* Image Usage & Resolution